Cargando…
Spotlight on valsartan–sacubitril fixed-dose combination for heart failure: the evidence to date
Heart failure is a global problem with elevated prevalence, and it is associated with substantial cardiovascular morbidity and mortality. Treating heart-failure patients has been a very challenging task. This review highlights the main pharmacological developments in the field of heart failure with...
Autor principal: | Vilela-Martin, José Fernando |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869613/ https://www.ncbi.nlm.nih.gov/pubmed/27274196 http://dx.doi.org/10.2147/DDDT.S84782 |
Ejemplares similares
-
Impact of Sacubitril/Valsartan on Patient Outcomes in Heart Failure: Evidence to Date
por: Akbar, Sara, et al.
Publicado: (2020) -
Effectiveness of sacubitril–valsartan in cancer patients with heart failure
por: Martín‐Garcia, Ana, et al.
Publicado: (2020) -
Sacubitril–valsartan in heart failure and multimorbidity patients
por: Rodil Fraile, Raquel, et al.
Publicado: (2018) -
Practical guidance on the use of sacubitril/valsartan for heart failure
por: Sauer, Andrew J., et al.
Publicado: (2018) -
Haemodynamic effects of sacubitril/valsartan in advanced heart failure
por: Gentile, Piero, et al.
Publicado: (2022)